EPCAM and colorectal carcinoma: The present study developed an anti-EpCAM monoclonal antibody (mAb) using cell-based immunization and screening (CBIS) methods (17) aiming to determine whether these anti-EpCAM mAbs induced antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC) or antitumor activity against CRC in a murine xenograft model.